Overview
Athira Q3 net loss decreases significantly compared to last year
Company continues exploring strategic alternatives to maximize stockholder value
Athira presents promising Phase 1 trial results for drug candidate ATH-1105
Outlook
Athira plans to advance ATH-1105 into ALS patient trials
Company continues to explore strategic alternatives to maximize stockholder value
Result Drivers
R&D EXPENSES - R&D expenses decreased significantly to $2.8 mln from $17.9 mln in the same period last year
G&A EXPENSES- G&A expenses were $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$1.68 | ||
Q3 Net Income | -$6.61 mln | ||
Q3 Operating Expenses | $6.87 mln | ||
Q3 Operating Income | -$6.87 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Press Release: ID:nGNX56ZfvP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)